Targeted Genetics announces issuance of additional adeno-associated virus (AAV) vector technology patent
Targeted Genetics Corporation announced the issuance of an additional patent related to the Company's adeno-associated virus (AAV) vector technology. U.S. patent #6,936,466, titled "Transcriptionally Activated AAV Inverted Terminal Repeats (ITRs) for Use with Recombinant AAV Vectors" covers the use of small regulatory control elements in conjunction with sequences within the AAV genome to drive gene expression. The use of vectors described in the patent may help to maximize gene Expression efficiency with little or no loss in viral payload.
"We believe that AAV vectors hold great promise in treating a wide variety of diseases," said H. Stewart Parker, President and Chief Executive Officer. "Targeted Genetics is pursuing several approaches, including the approach outlined in this patent, to expand the utility of AAV vectors. Utilizing sequences contained within the AAV genome to drive expression increases our flexibility with respect to vector design, which may allow us to deliver genes that might not ordinarily fit into a single AAV vector."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.